Re: Re: Diflucan Not Working

[Guest guest]

I don't know how long you've been on anti-fungals but it took

weeks for it to gain the upper hand on my candida. Too little and

the yeast continued growing, too much and the toxins from the die

off were even worse. It was a very tough balancing act requiring

multiple actions in combination with each other.

Carl Grimes

Healthy Habitats LLC

-----

On Sat Nov 07 22:35:43 CST 2009, Joe Salowitz

<josephsalowitz@...> wrote:

> If Diflucan (fluconazole) is NOT working, this current journal

> article, that I have cut and pasted below, advises using one of

> the Echinocandins, which, according to this

> article, have  " fungicidal activity against most Candida spp.,

> including strains that are fluconazole-resistant. " Fluconazole is

> the generic name for Diflucan.

>  

> Show this journal article to a doctor, to get him to prescribe

> one of these medicines. If you just tell him that " you read about

> it somewhere " it won't carry as much clout, as showing him the

> actual article. Sorry that all I can show you is the Abstract. My

> " Magic Library Card " couldn't get me the full-text of this

> article.

>  

> It's nice to see you posting again, Pete.

>  

> Good luck, and God Bless,

> Joe

>

> This is article I got from library on " the newest class of

> antifungals " :

>

> Published Online, 1 September 2009, www.theannals.com, DOI

> 10.1345/aph.1M237.

>

> The ls of Pharmacotherapy: Vol. 43, No. 10, pp. 1647-1657.

> DOI 10.1345/aph.1M237

> © 2009 Harvey Whitney Books Company.

>  

> INFECTIOUS DISEASES

>  

> Echinocandins: The Newest Class of Antifungals

>  

> Allana J Sucher, PharmD BCPS

>  

> at time of writing, Associate Professor of Pharmacy Practice,

> Lloyd L. School of Pharmacy, Palm Beach Atlantic

> University, West Palm Beach, FL; now, Associate Professor of

> Pharmacy Practice, Regis University School of Pharmacy, Denver,

> CO

>  

> Elias B Chahine, PharmD BCPS

>  

> Assistant Professor of Pharmacy Practice, Lloyd L. School

> of Pharmacy, Palm Beach Atlantic University

>  

> Holly E Balcer, PharmD BCPS

>  

> Clinical Pharmacy Specialist, Roper St. Francis Healthcare

> System, ton, SC

>  

>  

> OBJECTIVE: To review the mechanism of action, antifungal spectrum

> of activity, pharmacodynamics, pharmacokinetics, clinical

> efficacy, and safety of the echinocandins.

>  

> DATA SOURCES: A MEDLINE search (1982?May 2009) was conducted for

> articles published in the English language using the key words

> caspofungin, micafungin, anidulafungin, and echinocandins.

>  

> STUDY SELECTION AND DATA EXTRACTION: Medicinal chemistry, in

> vitro, and animal studies, as well as human trials were reviewed

> for information on the pharmacodynamics, pharmacokinetics,

> efficacy, and safety of each echinocandin. Clinical trials were

> reviewed and included to compare and contrast the available

> echinocandins.

>  

> DATA SYNTHESIS: Three echinocandin antifungal agents are

> currently approved for use in the US: caspofungin, micafungin,

> and anidulafungin. The echinocandins have a unique mechanism of

> action, inhibiting ?-(1,3)-D-glucan synthase, an enzyme that is

> necessary for the synthesis of an essential component of the cell

> wall of several fungi. The echinocandins display fungistatic

> activity against Aspergillus spp. and fungicidal activity against

> most Candida spp., including strains that are

> fluconazole-resistant. The echinocandins have been shown to be

> efficacious for the treatment of esophageal candidiasis,

> candidemia, and invasive candidiasis. In addition, caspofungin

> has demonstrated efficacy as empiric treatment of febrile

> neutropenia and salvage therapy for the treatment of invasive

> aspergillosis, and it is the only echinocandin approved for use

> in pediatric patients. Micafungin is the only echinocandin

> approved for use as prophylaxis against Candida

> infections in patients undergoing hematopoietic stem cell

> transplantation. Overall, resistance to echinocandins is still

> rare, and all agents are well tolerated, with similar adverse

> effect profiles and few drug?drug interactions.

>  

> CONCLUSIONS: Echinocandins, the newest addition to the arsenal of

> antifungals, offer potential advantages over other classes of

> agents. Clinicians should assess their distinguishing

> characteristics, including route of metabolism, drug interaction

> profile, and approved indications for use, when determining which

> agent to include on a formulary.

>  

>  

> Key Words: anidulafungin, antifungal, caspofungin, echinocandins,

> fungal infections, micafungin

>  

> Published Online, September 1, 2009. www.theannals.com, DOI

> 10.1345/aph.1M237

>  

>

>